Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BIVI Biovie Inc
- Stocks
- Healthcare
- NASDAQ: BIVI
Price (delayed)
$1.09
Market cap
$20.23M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.61
Enterprise value
-$2.55M
BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of
Highlights
BIVI's debt has shrunk by 96% YoY and by 4.1% QoQ
The EPS has soared by 83% YoY and by 53% from the previous quarter
BIVI's equity is up by 15% year-on-year but it is down by 9% since the previous quarter
BIVI's quick ratio is down by 46% from the previous quarter
Key stats
What are the main financial stats of BIVI
Market
Valuations
Earnings
Shares outstanding
18.56M
Market cap
$20.23M
Enterprise value
-$2.55M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$19.19M
Net income
-$18.99M
EBIT
-$18.23M
EBITDA
-$17.9M
Free cash flow
-$17.42M
Per share
Balance sheet
Liquidity
EPS
-$1.61
EPS diluted
-$1.61
Free cash flow per share
-$0.94
Book value per share
$1.18
Revenue per share
$0
TBVPS
$1.3
Total assets
$24.66M
Total liabilities
$2.84M
Debt
$366,430
Equity
$21.82M
Working capital
$21.17M
Debt to equity
0.02
Current ratio
9.32
Quick ratio
9.09
Net debt/EBITDA
1.27
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-80%
Return on equity
-102.8%
Return on invested capital
N/A
Return on capital employed
-82.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIVI stock price
How has the Biovie stock price performed over time
Intraday
-0.91%
1 week
-11.38%
1 month
32.75%
1 year
-77.98%
YTD
-45.5%
QTD
11.22%
Financial performance
How have Biovie's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.19M
Net income
-$18.99M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 50% YoY and by 20% QoQ
The net income is up by 48% year-on-year and by 22% since the previous quarter
Price vs fundamentals
How does BIVI's price correlate with its fundamentals
Growth
What is Biovie's growth rate over time
Valuation
What is Biovie stock price valuation
P/E
N/A
P/B
0.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 83% YoY and by 53% from the previous quarter
The price to book (P/B) is 91% lower than the 5-year quarterly average of 10.7 and 15% lower than the last 4 quarters average of 1.1
BIVI's equity is up by 15% year-on-year but it is down by 9% since the previous quarter
Efficiency
How efficient is Biovie business performance
BIVI's ROE has soared by 66% YoY and by 27% QoQ
The company's return on assets rose by 40% YoY and by 19% QoQ
Dividends
What is BIVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIVI.
Financial health
How did Biovie financials performed over time
BIVI's total liabilities has dropped by 78% year-on-year but it has soared by 60% since the previous quarter
BIVI's quick ratio is down by 46% from the previous quarter
BIVI's debt is 98% lower than its equity
BIVI's debt has shrunk by 96% YoY and by 4.1% QoQ
BIVI's debt to equity has plunged by 95% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.